Journals / Uludağ Üniversitesi Tıp Fakültesi Dergisi / 2019 / Cilt: 45 - Sayı: 2

Drug Eruptions

İlaç Erupsiyonları

Pages
231–241
Publication Date
2019-08-01
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Drugs should not be used unless absolutely necessary, society should be informed repeatedly and the importance of rational drug use should always be kept on the agenda.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Drug eruption is a major health problem.
📊
Key Findings & Data:While most drug eruptions are mild, self-limited, some has life-threatening potentional and a very small number of it may be fatal.
💡
Conclusion & Impact:Drugs should not be used unless absolutely necessary, society should be informed repeatedly and the importance of rational drug use should always be kept on the agenda.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:ilaç erupsiyonu · nedensellik değerlendirmesi · drug eruptions

Abstract

Drug eruption is a major health problem. While most drug eruptions are mild, self-limited, some has life-threatening potentional and a very small number of it may be fatal. Drug eruptions can mimic any kind of dermatoses. Despite all the difficulties the diagnosis of drug eruption is mainly based on clinical findings. What’s essential in clinical approach is to show the association between the drug and the eruption. There’s a few causality assessment scales such as “Naranjo Adverse Drug Reaction Probability Scale” and “Causality Assessment provided by World Health Organization-Uppsala Monitoring Centre” should be used if there’s any suspicion. Prevention should be a priority while dealing with drug reactions. Drugs should not be used unless absolutely necessary, society should be informed repeatedly and the importance of rational drug use should always be kept on the agenda.

Özet

İlaç erupsiyonu önemli bir sağlık sorunudur. Çoğu ilaç erupsiyonu hafif seyrederken, bazıları hayatı tehdit edici özellikte, çok az bir kısmı da ölümcül olabilmektedir. İlaç erupsiyonları her türlü dermatozu taklit edebilir. Tüm güçlüklere rağmen ilaç erüpsiyonu tanısı esas olarak klinik bulgulara dayanır. Klinik yaklaşımda esas olan ilaç ilişkisinin ortaya konmasıdır. Bu açıdan yapılacak bir nedensellik değerlendirmesi için Naronjo İlaç Yan Etki Olasılık Ölçeği ve Dünya Sağlık Örgütü - Uppsala İzlem Merkezi’ne ait Nedensellik Değerlendirme Sistemi gibi geliştirilmiş birtakım ölçekler vardır. Reaksiyon şüphesi olan olgularda kullanılmalıdır. İlaç reaksiyonlarında öncelikli yaklaşım önlenmesine yönelik çalışmalara ağırlık verilmesidir. Bunun için mutlak ihtiyaç olmadıkça ilaçlar kullanılmamalı, toplum bu konuda tekrar tekrar bilgilendirilmeli ve akılcı ilaç kullanımına önem verilmelidir.

🔖

Cite This Article

ÖZÇELİK, S. (2019). Drug Eruptions. Uludağ Üniversitesi Tıp Fakültesi Dergisi, Cilt: 45 - Sayı: 2, 231–241. https://ajindex.com/articles/134855

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (17)

  1. Bachot N, Roujeau JC. Differential diagnosis of severe cutaneous drug eruptions. American journal of clinical dermatology 2003;4:561-72
  2. Svensson CK, Cowen EW, Gaspari AA. Cutaneous drug reactions. Pharmacological reviews 2001;53:357-79
  3. DeLeo VA. Skin testing in systemic cutaneous drug reactions. Lancet 1998;352:1488-90
  4. Bigby M. Rates of cutaneous reactions to drugs. Archives of dermatology 2001;137:765-70
  5. Pudukadan D, Thappa DM. Adverse cutaneous drug reactions: clinical pattern and causative agents in a tertiary care center in South India. Indian journal of dermatology, venereology and leprology 2004;70:20-4
  6. Stern RS. Clinical practice. Exanthematous drug eruptions. The New England journal of medicine 2012;366:2492-501
  7. Warnock JK, Morris DW. Adverse cutaneous reactions to antidepressants. American journal of clinical dermatology 2002;3:329-39
  8. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA: the journal of the American Medical Association 1998;279:1200-5
  9. Liao PJ, Shih CP, Mao CT, Deng ST, Hsieh MC, Hsu KH. The cutaneous adverse drug reactions: risk factors, prognosis and economic impacts. International journal of clinical practice 2013;67:576-84
  10. U.S. Department of Health & Human Services F. Preventable Adverse Drug Reactions: A Focus on Drug Interactions2009
  11. Wolf R, Davidovici B. Severe cutaneous adverse drug reactions: who should treat, where and how?: Facts and controversies. Clinics in dermatology 2010;28:344-8
  12. Hiware S, Shrivastava M, Mishra D, Mukhi J, Puppalwar G. Evaluation of Cutaneous Drug Reactions in Patients Visiting Out Patient Departments of Indira Gandhi Government Medical College and Hospital (IGGMC and H), Nagpur. Indian journal of dermatology 2013;58:18-21
  13. Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs. The New England journal of medicine 1994;331:1272-85
  14. Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet (London, England) 2000;356:1255-9
  15. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA et al. A method for estimating the probability of adverse drug reactions. Clinical pharmacology and therapeutics 1981;30:239-45
  16. Justiniano H, Berlingeri-Ramos AC, Sanchez JL. Pattern analysis of drug-induced skin diseases. The American Journal of dermatopathology 2008;30:352-69
  17. Weyers W, Metze D. Histopa